With the rapid onset of game-changing injectable emicizumab [HEMLIBRA] therapy for hemophilia, coagulation laboratories face a new challenge. On the occasions when HEMLIBRA-treated hemophiliacs need factor VIII concentrate therapy, or if there is a desire to test for residual factor VIII, what means does the laboratory possess?
Posts - Quick Question Archive
Mar 31, 2020 2:09pm
1 Comment
Mar 31, 2020 1:18pm
Our March, 2020 Quick Question, "How does your facility measure extended half-life factor VIII concentrate therapy?" drew 24 votes, reflecting the number of laboratories serving Hemophilia and Bleeding Disorders services worldwide. Here are the answers:
0 Comments
Mar 2, 2020 9:11am
Look to the right for our March, 2020 Quick Question, "How does your facility measure extended half-life factor VIII concentrate therapy?" After you select your answer please add your comments by sending an email to george@fritsmafactor.com.
0 Comments
Mar 1, 2020 7:52pm
Our February, 2020 Quick Question, which drew 114 answers, asks, "For chronic bleeds, poor wound healing with normal PT
, PTT
, FG
0 Comments
